Iovance Biotherapeutics shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $20 to $23.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $20 to $23.
May 23, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird maintained an Outperform rating on Iovance Biotherapeutics and raised its price target from $20 to $23, resulting in higher trading.
Iovance Biotherapeutics shares are trading higher due to Baird's maintained Outperform rating and increased price target from $20 to $23. This positive outlook from a reputable analyst firm is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100